Jiangsu Hengrui Pharmaceuticals (SHA:600276) unit Suzhou Shengdiya Biopharmaceutical received China's regulatory approval to start clinical trials for SHR-5421.
The approval is for the anti-tumor drug's clinical research in multiple myeloma, according to a Tuesday filing with the Shanghai bourse.
Shares of the pharmaceutical company rose 2% in recent trade.
Henan Yuneng (SHE:001896) received a warning from the China Securities Regulatory Commission's Henan Bureau for breaches in disclosure, according to a Shenzhen bourse filing on Wednesday.The regulator's investigation found that the power company failed to publish complete information and risk warnings for an equity investment transaction in February, and failed to establish and implement an insider information registration management system.The company's shares dropped nearly 7% during the afternoon trade.
Taiwan's consumer confidence index (CCI) slipped to 62.08 in May, down 0.39 points from April, the Economic Development Research Center at National Central University said Wednesday.The decline was driven by weaker sentiment across five sub-indicators, with confidence in stock investment opportunities posting the largest monthly drop.The sub-indicators that dropped are investing in stocks, which recorded the largest decline, purchasing durable goods, domestic economic outlook, household financial situation and employment opportunities. Meanwhile, expectations for price levels over the next six months recorded the only increase among the six indicators.All six core sub-indicators point toward pessimism among consumers, the report said.
New Zealand shares ended higher on Wednesday as investors digested the Reserve Bank of New Zealand's decision to hold the official cash rate steady.The S&P/NZX 50 Index rose 1.21% or 158.07 points to close at 13,227.81.The Reserve Bank of New Zealand's (RBNZ) monetary policy committee decided to keep the official cash rate steady at 2.25%, according to a statement.Iran said on Tuesday that the US had breached a ceasefire by striking targets near the Strait of Hormuz, potentially complicating efforts to end the war, according to a Tuesday Reuters report.In corporate news, Scales (NZE:SCL) reaffirmed its market guidance of an underlying net profit after tax attributable to shareholders of between NZ$50 million and NZ$55 million for the full year.Air New Zealand (ASX:AIZ, NZE:AIR) informed customers of further flight cuts from August to October amidst a jet fuel crisis in the wake of the conflict in the Middle East, according to a report by Radio New Zealand.